- Home
- HBT vs ORIC Comparison
HBT vs ORIC Comparison
Compare HBT & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- ORIC
- Stock Information
- Founded
- HBT 1920
- ORIC 2014
- Country
- HBT United States
- ORIC United States
- Employees
- HBT N/A
- ORIC N/A
- Industry
- HBT Major Banks
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- ORIC Health Care
- Exchange
- HBT Nasdaq
- ORIC Nasdaq
- Market Cap
- HBT 812.0M
- ORIC 974.1M
- IPO Year
- HBT 2019
- ORIC 2020
- Fundamental
- Price
- HBT $25.98
- ORIC $11.02
- Analyst Decision
- HBT Buy
- ORIC Strong Buy
- Analyst Count
- HBT 5
- ORIC 10
- Target Price
- HBT $29.00
- ORIC $17.33
- AVG Volume (30 Days)
- HBT 24.9K
- ORIC 864.1K
- Earning Date
- HBT 10-20-2025
- ORIC 11-11-2025
- Dividend Yield
- HBT 3.26%
- ORIC N/A
- EPS Growth
- HBT 8.10
- ORIC N/A
- EPS
- HBT 2.42
- ORIC N/A
- Revenue
- HBT $229,851,000.00
- ORIC N/A
- Revenue This Year
- HBT $8.60
- ORIC N/A
- Revenue Next Year
- HBT $2.42
- ORIC N/A
- P/E Ratio
- HBT $10.66
- ORIC N/A
- Revenue Growth
- HBT 4.61
- ORIC N/A
- 52 Week Low
- HBT $19.46
- ORIC $3.90
- 52 Week High
- HBT $27.02
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- HBT 52.25
- ORIC 60.14
- Support Level
- HBT $25.51
- ORIC $10.36
- Resistance Level
- HBT $26.43
- ORIC $11.20
- Average True Range (ATR)
- HBT 0.58
- ORIC 0.47
- MACD
- HBT -0.06
- ORIC 0.10
- Stochastic Oscillator
- HBT 43.17
- ORIC 84.79
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.